⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for fgfr3

Every month we try and update this database with for fgfr3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell CarcinomaNCT02401542
Locally Advance...
Urinary Bladder...
Urological Dise...
Vofatamab
Docetaxel
Placebo
18 Years - Rainier Therapeutics
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsNCT04197986
Upper Tract Uro...
Urothelial Blad...
Infigratinib
Placebo
18 Years - QED Therapeutics, Inc.
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerNCT04917809
Bladder Cancer
Recurrent Bladd...
FGFR3 Gene Muta...
Erdafitinib
18 Years - Memorial Sloan Kettering Cancer Center
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursNCT05363605
Advanced Solid ...
Head and Neck S...
Bladder Carcino...
Susceptible FGF...
FGFR3
FGFR3 Overexpre...
FGFR3 Receptor
FGFR3 Protein O...
Ovarian Cancer
Colorectal Canc...
Breast Cancer
Liver Cancer
Lung Cancer
Gastric Cancer
[225Ac]-FPI-196...
[111In]-FPI-196...
vofatamab
18 Years - Fusion Pharmaceuticals Inc.
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsNCT04197986
Upper Tract Uro...
Urothelial Blad...
Infigratinib
Placebo
18 Years - QED Therapeutics, Inc.
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsNCT01752920
Solid Tumor
Derazantinib lo...
Derazantinib mi...
Derazantinib hi...
Derazantinib at...
18 Years - Basilea Pharmaceutica
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: